Prolocor to Participate at Biotech Showcase 2022
January 10, 2022 09:00 ET | Prolocor Inc
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Prolocor Inc, a healthcare startup developing an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets, today...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
January 10, 2022 07:30 ET | Cognition Therapeutics, Inc.
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Logo.jpg
INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING AND BIOTECH SHOWCASE, JANUARY 10-19, 2022 
January 05, 2022 09:00 ET | Invectys, Inc.
Houston, Texas, USA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
December 23, 2021 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
respirerx.jpg
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™
December 14, 2021 08:18 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to discover and develop innovative and revolutionary...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
January 11, 2021 07:46 ET | Cyclacel
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance
January 05, 2021 09:44 ET | Cognition Therapeutics, Inc.
Pittsburgh, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
December 30, 2020 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
January 13, 2020 07:00 ET | Cyclacel
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. ...
jpg.jpg
Incysus Therapeutics to Present at Biotech Showcase 2020
January 09, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...